Literature DB >> 21075432

FOXP3+ regulatory T-cells are abundant in vulvar Paget's disease and are associated with recurrence.

Joshua Z Press1, Kimberly H Allison, Rochelle Garcia, Elise N Everett, Ellen Pizer, Ron E Swensen, Hisham K Tamimi, Heidi J Gray, William A Peters, Barbara A Goff.   

Abstract

OBJECTIVE: To characterize clinical features of vulvar Paget's disease, and examine the quantity of immunosuppressive regulatory T-cells in vulvar Paget's tissue.
METHODS: Vulvar Paget's cases from 1992 to 2007 from two institutions were identified by pathology database search. Regulatory T-cells were identified with FOXP3 immunohistochemistry and quantified at the dermal-epidermal junction using image analysis software. Thirteen non-neoplastic inflammatory cases were stained for comparison.
RESULTS: Cases included 33 women treated for primary vulvar Paget's, and 7 referred at recurrence. Of the 24 primary cases with greater than 5 months follow-up, recurrence was documented in 12/24(50%). Eight women (20%) recurred multiple times, but no recurrences were invasive. Significantly more patients with positive margins developed recurrent disease (82% vs 23%, p=0.01). Secondary neoplasms occurred in 10/40(25%). FOXP3+ cells at the dermal-epidermal junction were quantified in 29 primary and 13 recurrent tissue samples. FOXP3+ cells were absent in surrounding normal vulvar skin. FOXP3+ cells averaged 66/HPF in primary vulvar Paget's and 66/HPF in recurrent Paget's, compared to 22/HPF in non-neoplastic inflammatory cases (p=0.0003, p=0.001). Primary cases with positive surgical margins had more FOXP3+ cells than those with negative margins (85 vs 49, p=0.01). Recurrent cases with positive margins had more FOXP3+ cells than negative cases (84 vs 33, p=0.06). FOXP3 levels in primary specimens were higher in cases which recurred (78 vs 35, p=0.02).
CONCLUSIONS: Increased regulatory T-cells may be associated with more extensive cases of vulvar Paget's disease that result in positive surgical margins and are associated with recurrence of disease, suggesting immunosuppression as a key factor.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21075432     DOI: 10.1016/j.ygyno.2010.10.019

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  The Possible Interaction between Receptor Activator of Nuclear Factor Kappa-B Ligand Expressed by Extramammary Paget Cells and its Ligand on Dermal Macrophages.

Authors:  Yumi Kambayashi; Taku Fujimura; Sadanori Furudate; Masayuki Asano; Aya Kakizaki; Setsuya Aiba
Journal:  J Invest Dermatol       Date:  2015-05-27       Impact factor: 8.551

2.  The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) Consensus Statements on Pre-invasive Vulvar Lesions.

Authors:  Mario Preti; Elmar Joura; Pedro Vieira-Baptista; Marc Van Beurden; Federica Bevilacqua; Maaike C G Bleeker; Jacob Bornstein; Xavier Carcopino; Cyrus Chargari; Margaret E Cruickshank; Bilal Emre Erzeneoglu; Niccolò Gallio; Debra Heller; Vesna Kesic; Olaf Reich; Colleen K Stockdale; Bilal Esat Temiz; Linn Woelber; François Planchamp; Jana Zodzika; Denis Querleu; Murat Gultekin
Journal:  J Low Genit Tract Dis       Date:  2022-06-21       Impact factor: 3.842

Review 3.  Metastatic Extramammary Paget's Disease: Pathogenesis and Novel Therapeutic Approach.

Authors:  Keitaro Fukuda; Takeru Funakoshi
Journal:  Front Oncol       Date:  2018-02-16       Impact factor: 6.244

Review 4.  Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review.

Authors:  Fulvio Borella; Mario Preti; Luca Bertero; Giammarco Collemi; Isabella Castellano; Paola Cassoni; Stefano Cosma; Andrea Roberto Carosso; Federica Bevilacqua; Niccolò Gallio; Chiara Benedetto; Leonardo Micheletti
Journal:  Int J Mol Sci       Date:  2020-12-27       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.